Archived Content
Save the Date - Next Event to Take Place May 16-18, 2016 in Philadelphia
The successful development and market access of new medicines is becoming increasingly reliant on harnessing an alliance ecosystem throughout the biopharma value chain. As a result, a growing number of strategic partnerships have driven the need for innovative and systematic methods, processes, and best practices for the successful execution and management of an expanding variety of agreements. As developers strive to derive as much value as possible from investments, what practical solutions exist to overcome innate and ubiquitous partnership challenges while improving organizational Alliance Management (AM) function and capability? Where are the greatest opportunities for enhancing the overall health and success of each partnership? How can diligent Alliance Management deliver a competitive advantage, drive value for stakeholders, and augment a firm's partnership competency from opportunistic to endemic?
Cambridge Healthtech Institute’s 12th Annual Strategic Alliance Management Congress, May 4-6, brings together senior alliance management, business development, technology transfer and licensing professionals, to network, share experiences, discuss case studies, and to highlight components that cultivate successful partnerships. Delegates will gain strategic insights, proven tools, methods, and perspectives from a variety of leaders advancing the art of alliance management.
KEYNOTE PROGRAM:
The Changing Landscape of Biopharmaceutical Alliances, Challenges in Alliance Management and Outlook for Continued Success
Dana Hughes
Vice President & Global Head,
Integration and Alliance
Management, Worldwide Business
Development Group, Pfizer
Erin Brubaker
Vice President, Alliance
Management, Worldwide Business
Development; Head, Alliance
Management Center of Excellence,
GlaxoSmithKline
CONFERENCE SESSIONS:
- An Alliance Manager’s Toolbox: Internal Strategies for Success & When Things Go Wrong
- Building, Enhancing and Continuously Improving Alliance Management Capability:
A Look into Sanofi, Bayer, Celgene and Astrazeneca’s New AM Initiatives
- Tackling the Challenges of an Alliance Manager in a Small Biotech
- Strategies for Companion Diagnostic and Academic Collaboration
- Improving Service- and Supply-Based Partnerships
- Reimagining Open-Access, Government and Multi-Stakeholder Partnerships
REASONS TO ATTEND:
- Connect with 100+ Attendees with Dedicated Networking Sessions
- Hear 20+ Executive-Level Presentations & Panel Discussions
- Discuss Challenges in AM during Informal Roundtables
- Participate in Top-Rated AM Training Workshops
- Learn from Real-World Case Studies by Leading Biopharma Companies
FEATURING AM LEADERS FROM:
- ACRES
- AstraZeneca
- Bayer Health Care Pharmaceuticals
- Biogen Idec
- Celgene Corporation
- Daiichi Sankyo
- Eisai
- Eli Lilly and Company
- Emergent BioSolutions
- GlaxoSmithKline
|
- ImmunoGen
- Kadmon
- Mesoblast
- NIH Office of Technology Transfer
- Pfizer
- Quintiles
- Sanofi
- Sanofi Oncology
- Skolkovo Innovation Center
- Vantage Partners
|
Day 1 | Day 2 | Day 3 | Short Courses